BG
ITRM

Bollard Group’s Iterum Therapeutics ITRM Stock Holding History

Bollard Group’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48
Closed – – 343
2022
Q1 		$0 Hold
48
– – ﹤0.01% 436
2021
Q4 		$0 Hold
48
– – ﹤0.01% 438
2021
Q3 		$0 Hold
48
– – ﹤0.01% 427
2021
Q2 		$2K Hold
48
– – ﹤0.01% 420
2021
Q1 		$1K Hold
48
– – ﹤0.01% 429
2020
Q4 		$1K Hold
48
– – ﹤0.01% 427
2020
Q3 		$1K Sell
48
-153
-76% -$2.04K ﹤0.01% 431
2020
Q2 		$4K Buy
+201
New +$7.98K ﹤0.01% 441

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Bollard Group's ITRM Position: Q2 2022 in Review

Bollard Group sold out of Iterum Therapeutics (ITRM) in Q2 2022, closing a stake of 48 shares.

Bollard Group first reported a position in ITRM in Q2 2020 and held it in 8 quarters. The position peaked at $4K in Q2 2020. 38 funds tracked by Wall St. Rank hold ITRM as of Q2 2022.

  • Bollard Group reported no remaining Iterum Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 48 Iterum Therapeutics shares in Q2 2022.
  • Bollard Group first reported a position in Iterum Therapeutics in Q2 2020 and held it in 8 quarters.
  • Bollard Group's Iterum Therapeutics position peaked at $4K in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.